Extended cycle multiphasic oral contraceptive kit

ABSTRACT

A multiphasic contraceptive kit for use to practice a multiphasic method of contraception that provides for sequentially administering to a female of child bearing age: (a) a Phase I composition containing a progestogen and an estrogen for about 4 to about 7 days; (b) a Phase II composition containing a progestogen and an estrogen for about 8 to about 16 days; (c) a Phase III composition containing a progestogen and an estrogen for about 4 to about 7 days; and (d) optionally, a Phase IV composition which is a placebo or a non-steroidal component, wherein the ethinyl estradiol equivalent amount of estrogen in the Phase II composition is at least 5 mcg greater than the ethinyl estradiol equivalent amount of estrogen in each of the Phase I and III compositions. Preferably the sequential administration is repeated the day following the completion of the administration of the Phase III compositions providing an extended cycle multiphasic oral contraceptive method.

RELATED CASES

This application is a divisional of application Ser. No. 11/078,300,filed Mar. 14, 2005, now U.S. Pat. No. 7,569,560, claims benefit of thatapplication under 35 U.S.C. §120, which claims benefit under 35 U.S.C.§119 of 60/554,621, filed on Mar. 19, 2004, and incorporates the entirecontents of both of those prior applications by reference.

BACKGROUND OF THE INVENTION

1. Field of the Invention

This invention is directed to a multiphasic estrogenic/progestogeniccontraceptive regimen that may be used for an extended period of time.In the multiphasic regimen of the present invention, the amount ofestrogen administered in an intermediate phase is greater than theamount of estrogen administered in the first and final phases. Theinventive regimen provides contraceptive efficacy and enables the userto maintain menstrual cycle control. A multiphase contraceptive kit thatmay be used to practice the method of this invention is alsocontemplated.

2. Related Background Art

Contraceptive compositions containing both estrogenic and progestogeniccompounds are known to be highly effective in controlling ovulation andconception. The progestogenic component of the composition is primarilyresponsible for the contraceptive efficacy of the composition, while theestrogenic component is included to reduce undesired side effects, suchas breakthrough bleeding or spotting. In fact, small amounts of estrogenhelp stabilize the endometrium and allow cyclic withdrawal bleeding,similar to the natural menstrual cycle.

The earliest of these estrogenic/progestogenic contraceptivecompositions was administered monophasically (fixed dose) and containeda relatively high level of estrogenic component. To minimize estrogen'smajor negative side effect on blood clotting factors, the dose ofestrogen was reduced over time. However, as estrogen doses decreased,the incidences of unwanted breakthrough bleeding or spotting havegenerally increased.

Multiphasic oral contraceptives were introduced to artificially simulatethe natural rise of progesterone over the cycle in an attempt to solvethis problem. A constant goal, however, has been to reduce theestrogenic potency of such compositions without reducing contraceptiveefficacy and increasing undesired side effects.

In U.S. Pat. No. 5,888,543, various regimens are disclosed where acombination of progestin and estrogen are administered in a monophasicor multiphasic regimens (varied dose, e.g., biphasic or triphasic). Inone embodiment, a combination of a progestin composition and an estrogencomposition is administered such that the daily dosage of the secondphase progestin is greater than the daily dosage of progestin in thefirst phase and the daily dosage of the second phase estrogen is greaterthan or equal to the daily dosage of estrogen in the first phase.

A particularly advantageous technique for reducing total estrogenicadministration is described in U.S. Pat. No. 4,962,098. This describes atriphasic method of contraception using a progestogen/estrogencombination in which the amount of estrogen is increased stepwise overthe three phases. The first phase is 4-7 days, the second phase is 5-8days and the third phase is 7-12 days. Preferably, the administration ofthe contraceptive compositions for the three phases will be 21 daysfollowed by a 7 day placebo period. For all three phases the progestogenis 0.5 to 1.5 mg of norethindrone acetate, while about 10 to 30 mcg ofethinyl estradiol is used in the first phase, about 20 to 40 mcg ofethinyl estradiol is used in the second phase and 30 to 50 mcg ofethinyl estradiol is employed in the third phase.

U.S. Pat. No. 5,010,070 is related to U.S. Pat. No. 4,962,098 anddiscloses a multiphasic contraceptive kit containing ethinyl estradioland norethindrone acetate in first, second, and third phasecompositions.

An extended oral contraceptive regimen is disclosed in U.S. Pat. No.5,898,032, where estrogen and progestin are administered in a combineddosage form, preferably monophasicly, for 60 to 110 consecutive days,followed by an administration free period of 3 to 10 days. The amount ofestrogen and progestin administered daily are equivalent to about 5-35mcg of ethinyl estradiol and about 0.025 to 10 mg of norethindroneacetate, respectively. In one particular embodiment, the combined dosageform is administered for 84 days followed by 7 pill free days. Followingthis particular regimen is said to result in four treatments andmenstrual cycles during the year.

There are, however, disadvantages to using an extended monophasic oralcontraceptive regimen. Typically, monophasic oral contraceptivesadministered for an extended period of time have poor initial cyclecontrol. Another disadvantage is that once breakthrough bleeding isunder control, the user becomes functionally amenorrheic.Psychologically, this does not reassure the user that she is notpregnant.

An extended cycle regimen that employs a multiphasic contraceptivemethod has not been described or suggested. A major concern is thatmultiphasic methods vary the ratio of estrogen to progestogen such thatthe amount of estrogen and/or progestogen administered in the finalphase, e.g., Phase III, is much greater than the amount of estrogenand/or progestogen administered in the initial phase, e.g., Phase I. Inan extended cycle regimen, where the cycle proceeds sequentially fromthe first phase through the final phase and repeats again starting withthe first phase, the dramatic decrease in estrogen and/or progestogenfrom the final phase to the first phase would increase the potential forbreakthrough bleeding, which is unacceptable.

An extended oral contraceptive regimen that reduces the risk that theuser becomes functionally amenorrheic while taking advantage of thebenefits of a multiphasic contraceptive method, e.g., reduce risk ofbreakthrough bleeding, improved control of bleeding, and effective meansof contraception, would be highly desirable to users.

SUMMARY OF THE INVENTION

The present invention is directed to a multiphasic method ofcontraception that provides for sequentially administering to a femaleof child bearing age (a) a Phase I composition containing a progestogenin an amount equivalent to about 0.5 to about 1.5 mg norethindroneacetate and an estrogen in an amount equivalent to about 5 to about 30mcg of ethinyl estradiol for about 4 to about 7 days; (b) a Phase IIcomposition containing a progestogen in an amount equivalent to about0.5 to about 1.5 mg of norethindrone acetate and an estrogen in anamount equivalent to about 10 to about 40 mcg of ethinyl estradiol forabout 8 to about 16 days; (c) a Phase III composition containing aprogestogen in an amount equivalent to about 0.5 to about 1.5 mg ofnorethindrone acetate and an estrogen in an amount equivalent to about 5to about 30 mcg of ethinyl estradiol for about 4 to about 7 days; and(d) optionally, a Phase IV composition which is a placebo or anon-steroidal component, such as for example, ferrous fumarate, forabout 2 to about 9 days, wherein the ethinyl estradiol equivalent amountof estrogen in the Phase II composition is at least 5 mcg greater thanthe ethinyl estradiol equivalent amount of estrogen in each of the PhaseI and III compositions.

In a particularly significant embodiment of the invention, thesequential administration of the Phase I, II, and III compositions isrepeated the day following the completion of the administration of thePhase III composition to provide an extended cycle multiphasic oralcontraceptive method. Preferably, the extended contraceptive cycle is ina range from about 42 to about 140 days, and, preferably, about 63 toabout 120 days.

Yet another embodiment of this invention is directed to a multiphasecombination and contraceptive kit comprising a package containing dailydosages of (a) a Phase I composition containing a progestogen in anamount equivalent to about 0.5 to about 1.5 mg of norethindrone acetateand an estrogen in an amount equivalent to about 5 to about 30 mcg ofethinyl estradiol; (b) a Phase II composition containing a progestogenin an amount equivalent to about 0.5 to about 1.5 mg of norethindroneacetate and an estrogen in an amount equivalent to about 10 to about 40mcg of ethinyl estradiol; (c) a Phase III composition containing aprogestogen in an amount equivalent to about 0.5 to about 1.5 mg ofnorethindrone acetate and an estrogen in an amount equivalent to about 5to about 30 mcg of ethinyl estradiol; and (d) optionally, a Phase IVcomposition which is a placebo or a non-steroidal component, wherein theethinyl estradiol equivalent amount of estrogen in the Phase IIcomposition is at least 5 mcg greater than the ethinyl estradiolequivalent amount of estrogen in each of the Phase I and IIIcompositions.

The kit may be designed for single cycle or extended cycle use. Forsingle cycle use the kit contains about 4 to about 7 dosages of thePhase I composition; about 8 to about 16 dosages of the Phase IIcomposition; and about 4 to about 7 dosages of the Phase IIIcomposition. For extended cycle use, the kit will preferably contain aplurality of groups of dosages of the Phase I, Phase II, and Phase IIIcompositions. Both the single cycle and extended cycle kits, optionallyand preferably, may contain about 2 to about 9 dosages of a Phase IVcomposition. Of course, it is also possible to practice the extendedcycle of this invention by employing a plurality of the above-describedkits for single cycle use.

DETAILED DESCRIPTION OF THE INVENTION

For the purposes of this invention, the designation “mcg” refers tomicrograms and “mg” to milligrams.

By practicing the multiphasic contraceptive method disclosed herein, auser advantageously improves control of menstrual bleeding while takingthe estrogenic/progestogenic contraceptive compositions of theinvention.

A notable feature of the invention is that the amount of estrogenadministered in the intermediate phase composition (Phase II) is greaterthan the amount of estrogen administered in each of the first and finalphase compositions (Phase I and Phase III). Moreover, it is desirable tohave the amount of estrogen administered in the first phase composition(Phase I) correspond to the amount of estrogen administered in the finalphase composition (Phase III). In one particularly preferred embodimentthe amount of ethinyl estradiol in the Phase II composition is at leastabout 5 mcg greater, preferably at least about 10 mcg greater, than theamount of ethinyl estradiol in each of the Phase I and Phase IIIcompositions.

In one particularly preferred embodiment the amount of estrogen in PhaseI is equivalent to about 20 mcg of ethinyl estradiol, the amount ofestrogen in Phase II is equivalent to about 25 mcg of ethinyl estradioland the amount of estrogen in the Phase III is equivalent to about 20mcg of ethinyl estradiol. In yet another particularly preferredembodiment the amount of estrogen in Phase I is equivalent to about 25mcg of ethinyl estradiol, the amount of estrogen in Phase II isequivalent to about 30 mcg of ethinyl estradiol and the amount ofestrogen in Phase III is equivalent to about 25 mcg of ethinylestradiol.

The progestogen may be selected, for example, from the group consistingof norethindrone acetate, drospirenone, trimegestone, norethindrone,levonorgestrel, desogestrel, 3-ketodesogestrel, gestodene and the like.The most preferred progestogen is norethindrone acetate. The estrogenmay be selected, for example, from the group consisting of ethinylestradiol, 17-β-estradiol, estradiol acetate, conjugated estrogens,mestranol, estrone and salts thereof. The most preferred estrogen isethinyl estradiol. The amount of progestogen and estrogen employed ineach Phase will be that amount which is equivalent in potency to theranges of norethindrone acetate and ethinyl estradiol, respectively,that are set forth herein. Determination of equivalent potency is wellunderstood and readily accomplished by those of ordinary skill in theart.

In the female body, the blood-rich mucous membrane lining the uterusknown as the endometrium, adapts to varying levels of estrogen in thebody. Without wishing to be bound by theory, it is believed that bycycling low amounts of estrogen (e.g., decreasing the amount of estrogenin the final phase of administration to levels corresponding to theinitial phase), the integrity of the endometrium may be maintained at anadequate state of at least about 3 to 5 mm thickness, thus reducing theundesirable occurrence of breakthrough bleeding. By maintaining theintegrity of the endometrium, the user may control discharge bleedingand extend her cycle. By varying the dose of estrogens the endometriumdoes not acclimate to a constant estrogenic dose. It is believed,without being bound by theory, that this up and down regulation of theestrogenic endometrium receptors results in the support of theendometrium.

The inventive multiphasic method of contraception sequentiallyadministers, to a female of child bearing age: (a) a Phase I compositioncomprising a progestogen in an amount equivalent to about 0.5 to about1.5 mg norethindrone acetate and an estrogen in an amount equivalent toabout 5 to about 30 mcg ethinyl estradiol; (b) a Phase II compositioncomprising a progestogen in an amount equivalent to about 0.5 to about1.5 mg norethindrone acetate and an estrogen in an amount equivalent toabout 10 to about 40 mcg ethinyl estradiol; (c) a Phase III compositioncomprising a progestogen in an amount equivalent to about 0.5 to about1.5 mg norethindrone acetate and an estrogen in an amount equivalent toabout 5 to about 30 mcg ethinyl estradiol; and (d) optionally, a PhaseIV composition which is a placebo or a non-steroidal component.Moreover, the ethinyl estradiol equivalent amount of estrogenadministered in the Phase II composition is at least about 5 mcggreater, preferably at least about 10 mcg greater, than the ethinylestradiol equivalent amount of estrogen administered in each of Phases Iand III.

In a preferred embodiment, the regimen is practiced in an extended cyclemanner. In the first cycle, Phase I is administered for about 4 to about7 days, Phase II is administered for about 8 to about 16 days, and PhaseIII is administered for about 4 to about 7 days. It is essential thatthe phases succeed each other in increasing order (i.e., I, II, andIII). Upon completion of Phase III, the user immediately repeats thecycle by starting Phase I again. Preferably, this may be repeated for aperiod of about 42 days to about 140 days, more preferably, about 63 toabout 120 days. When the user desires to discontinue the regimen, andexperience a discharge bleeding, she will either begin administering thePhase IV composition or go pill free for a period of about 2 to about 9days, preferably about 4 to about 9 days. By practicing this regimen,the user may reduce the number of menstrual cycles she will have to aslittle as three per year.

In another embodiment, the user may choose to psychologically reassureherself that she is not pregnant by having a monthly discharge bleeding.To do so, she would practice the inventive regimen in a single cyclemanner and upon completion of Phase III, either begin taking a Phase IVcomposition or simply take no pill for about 2 to about 9 days. Forexample, in a preferred embodiment of the single cycle method the userwould follow the regimen where Phase I is administered for about 4 toabout 7 days, Phase II is administered for about 8 to about 16 days,Phase III is administered for about 4 to about 7 days, and Phase IV isadministered for about 2 to about 9 days. Ideally, this embodiment ofthe inventive method is practiced for a 28 day period (menstrual cycle).It is essential that the phases succeed each other in increasing order(i.e., I, II, III, IV). After the Phase IV composition is administered,the user may start the cycle again beginning with the Phase Icomposition.

The Phase IV composition may serve as a cleansing period. In Phase IV, aplacebo or a non-steroidal component may be administered.

In a particularly preferred embodiment, the Phase IV composition is anon-steroidal component comprising an iron supplement. Suitable ironsupplements include, for example, ferrous fumarate, ferrous sulfate,ferrous gluconate, iron polysaccharides, and mixtures thereof. Thepreferred iron supplement is ferrous fumerate.

Preferably, the iron supplement is equivalent to not more than about 75mg ferrous fumerate.

The compositions used herein preferably contain norethindrone acetate, aprogestogenic component having less potency—and, comcomitantly,producing lower incidence of breakthrough bleeding—than otherprogestogenic agents, e.g., norethindrone.

As noted previously, it is essential that the method of this inventionbe practiced by administration of the compositions in a numeric sequencewith the Phase I composition administered first, the Phase IIcomposition administered second, etc. If packaging and/or otherrequirements dictate, the method and kit described herein can beemployed as part of a larger scheme for contraception or treatment ofgynecological disorders. While the sequence in which Applicant'scombinations are administered is important to their operation, it shouldbe kept in mind that variations in timing and dosage can be toleratedwhen medical considerations so dictate.

Although ethinyl estradiol is the estrogenic compound exemplified inthis invention, it should be understood that other estrogenic compoundsmay be substituted as long as the equivalent amount of estrogen isadministered. Other suitable estrogenic compounds include, for example,17β-estradiol, estradiol acetate conjugated estrogens, mestranol,estrone, and salts thereof. Preferred salts of estrone include, but arenot limited to the sodium and piperate salt. For the conjugatedestrogens, 1.25 mg conjugated estrogens is equivalent to a daily dose of15 mcg ethinyl estradiol.

Similarly, norethindrone acetate is the progestogenic compoundexemplified in this invention. However, other suitable progestogeniccompounds may be substituted so long as the equivalent amount ofprogestogen is administered. Suitable progestogenic compounds include,but are not limited to, levonorgestrel, desogestrel, drospirenone,trimegestone, 3-ketodesogestrel, gestodene, and the like.

The compositions employed in accordance with the invention in Phases Ithrough IV will more preferably have the administration times and drugcontents set forth in the Tables 1 and 2, when a four-phase system isused. Each table sets forth relevant values for one of Applicant'spreferred embodiments, or configurations, for administration of thesystem to females.

TABLE 1 mg Norethindrone Phase Days acetate mcg EE mg Fumarate I 5 1.025 0 II 11 1.0 30 0 III 5 1.0 25 0 IV 7 0 0 75

TABLE 2 mg Norethindrone Phase Days acetate mcg EE mg Fumarate I 5 1.020 0 II 14 1.0 25 0 III 5 1.0 20 0 IV 4 0 — 75

It should be noted that these tables are presented for illustrativepurposes only. For example, the cycles described in Table 1 and Table 2could be modified by dropping the Phase IV composition and sequentiallyadministering Phase I, II, and III and then immediately repeating theadministration of Phase I, II, and III for an extended cycle method oforal contraception. The substitution of functionally equivalent amountsand kinds of reagent(s) in these schemes is contemplated. For example,the use of sugar or other placebo in place of all or part of the ferrousfumarate is envisioned.

In addition, the use of other conventional additives, e.g., fillers,colorants, polymeric binders, and the like is also contemplated. Ingeneral any pharmaceutically-acceptable additive which does notinterfere with the function of the active components can be used in oneor more of the compositions.

Suitable carriers with which the compositions can be administeredinclude lactose, starch, cellulose derivatives and the like used insuitable amounts. Lactose is a preferred carrier. Mixtures of carriersare operable.

The terms “method” and “kit” are used herein to encompass any drugdelivery systems via the use of which the 3- or 4-phase scheme outlinedabove can be effectively administered to human females. Combinations ofvarious dosage forms are operable.

The multiphase combination and contraceptive kit of this invention is apackage containing the daily dosages of Phase I, II, and IIIcompositions and optionally the daily dosages of Phase IV compositionfor practicing the method of this invention. Various types of packagesfor holding contraceptives are well known and it is contemplated thatany such packaging may be used or altered for use in the practice of thepresent invention. For example, a single cycle package of the presentinvention would preferably include about 4 to about 7 dosages of thePhase I composition; about 8 to about 16 dosages of the Phase IIcomposition; and about 4 to about 7 dosages of the Phase IIIcomposition. A preferred embodiment of the single cycle package may alsoinclude about 2 to about 9 dosages of the Phase IV composition. Itshould be readily apparent that groups of dosages or a plurality ofsingle cycle packages could be used to practice the extended cyclemultiphasic oral contraceptive method of this invention. The pluralityof packages could be the same or different. For example, the user couldhave three or four packages that each contain the above-describeddosages of Phase I, II, and III compositions. Preferably, the kit wouldinclude about 2 to about 9 groups, more preferably about 3 to about 5groups, of dosages of the Phase I, II, and III compositions. In anotherembodiment, each group of dosages of the Phase I composition containsabout 5 dosages, each group of dosages of the Phase II compositioncontains about 11 to about 14 dosages, and each group of dosages of thePhase III composition contains about 5 dosages. If desired, the lastpackage to be used in the extended cycle administration could alsocontain the optional Phase IV composition that is taken prior tobeginning the next extended cycle administration. Of course, a singlepackage may contain all the dosages necessary for an extended cycleadministration. In this case, there would be a plurality of groups ofdosages of the Phase I, II, and III compositions, and optionally a lastgroup of dosages of the Phase IV composition. In such a package thedosages would be taken sequentially and grouped such that each group ofdosages would be administered in a cyclical fashion (e.g., I, II, III,I, II, III, I, II, III, I, II, III for a four cycle extended cyclefollowed optionally by IV).

While the invention has been described above with reference to specificembodiments thereof, it is apparent that many changes, modifications,and variations can be made without departing from the inventive conceptdisclosed herein. Accordingly, it is intended to embrace all suchchanges, modifications, and variations that fall within the spirit andbroad scope of the appended claims. All patent applications, patents,and other publications cited herein are incorporated by reference intheir entirety.

1. A multiphase combination and contraceptive kit comprising a packagecontaining daily dosages of: (a) a Phase I composition containing aprogestogen in an amount equivalent to about 0.5 to about 1.5 mg ofnorethindrone acetate and an estrogen in an amount equivalent to about 5to about 30 mcg of ethinyl estradiol; (b) a Phase II compositioncontaining a progestogen in an amount equivalent to about 0.5 to about1.5 mg of norethindrone acetate and an estrogen in an amount equivalentto about 10 to about 40 mcg of ethinyl estradiol; and (c) a Phase IIIcomposition a progestogen in an amount equivalent to containing about0.5 to about 1.5 mg of norethindrone acetate and an estrogen in anamount equivalent to about 5 to about 30 mcg of ethinyl estradiol;wherein the ethinyl estradiol equivalent amount of estrogen in the PhaseII composition is at least 5 mcg greater than the ethinyl estradiolequivalent amount of estrogen in each of the Phase I and IIIcompositions, wherein the ethinyl estradiol equivalent amount ofestrogen in the Phase III composition is equal to the ethinyl estradiolequivalent amount of estrogen in the Phase I composition, and whereinthe sequential administration of the Phase I, II, and III compositionsis repeated the day following the completion of the administration ofcomposition III to provide an extended contraceptive cycle, there is nodecrease in the norethindrone acetate equivalent amount of progestogenfrom the administration of the Phase III composition to theadministration of the Phase I composition in the extended contraceptivecycle and the extended contraceptive cycle is from about 42 to about 140days.
 2. The kit according to claim 1, wherein the progestogen isselected from the group consisting of norethindrone acetate,drospirenone, trimegestone, norethindrone, levonorgestrel, desogestrel,3-ketodesogestrel, gestodene, and mixtures thereof.
 3. The kit accordingto claim 2, wherein the progestogen is norethindrone acetate.
 4. The kitaccording to claim 1, wherein the estrogen is selected from the groupconsisting of ethinyl estradiol, 17β-estradiol, estradiol acetate,conjugated estrogens, mestranol, estrone, and salts thereof.
 5. The kitaccording to claim 4, wherein the estrogen is ethinyl estradiol.
 6. Thekit according to claim 1, wherein the kit further comprises about 2 toabout 9 dosages of a Phase IV composition which is a placebo or anon-steroidal component to be administered upon completion of theextended contraceptive cycle.
 7. The kit according to claim 6, whereinthe norethindrone acetate equivalent amount of progestogen in the PhaseI, II and III compositions is about 1 mg of norethindrone acetate. 8.The kit according to claim 7, wherein the ethinyl estradiol equivalentamount of estrogen in the Phase I composition is about 25 mcg ethinylestradiol, the ethinyl estradiol equivalent amount of estrogen in thePhase II composition is about 30 mcg of ethinyl estradiol, the ethinylestradiol equivalent amount of estrogen in the Phase III composition isabout 25 mcg of ethinyl estradiol, and the Phase IV composition containsabout 75 mg of ferrous fumarate.
 9. The kit according to claim 8,wherein the estrogen and progestogen in the Phase I, II and IIIcompositions are, respectively, ethinyl estradiol and norethindroneacetate.
 10. The kit according to claim 7, wherein the ethinyl estradiolequivalent amount of estrogen in the Phase I composition is about 20 mcgethinyl estradiol, the ethinyl estradiol equivalent amount of estrogenin the Phase II composition is about 25 mcg of ethinyl estradiol, theethinyl estradiol equivalent amount of estrogen in the Phase IIIcomposition is about 20 mcg of ethinyl estradiol, and the Phase IVcomposition contains about 75 mg of ferrous fumarate.
 11. The kitaccording to claim 10, wherein the estrogen and progestogen in the PhaseI, II and III compositions are, respectively, ethinyl estradiol andnorethindrone acetate.
 12. The kit according to claim 1, wherein the kitcontains a plurality of groups of dosages of Phase I, II, and IIIcompositions, wherein each group of dosages of Phase I compositioncontains about 4 to about 7 dosages, each group of dosages of Phase IIcompositions contains about 8 to about 16 dosages and each group ofdosages of Phase III compositions contains about 4 to about 7 dosages.13. The kit according to claim 12, wherein the number of groups ofdosages of Phase I, II, and III compositions is from about 2 to about 9.14. The kit according to claim 13, wherein said kit contains one groupof dosages of a Phase IV composition that amounts to about 2 to about 9daily dosages.
 15. The kit according to claim 14, wherein thenorethindrone acetate equivalent amount of progestogen in the Phase I,II, and III compositions is about 1 mg of norethindrone acetate.
 16. Thekit according to claim 15, wherein the ethinyl estradiol equivalentamount of estrogen in the Phase I composition is about 20 mcg of ethinylestradiol, the ethinyl estradiol equivalent amount of estrogen in thePhase II composition is about 25 mcg of ethinyl estradiol, and theethinyl estradiol equivalent amount of estrogen in the Phase IIIcomposition is about 20 mcg of ethinyl estradiol.
 17. The kit accordingto claim 16, wherein the estrogen and progestogen in the Phase I, II andIII compositions are, respectively, ethinyl estradiol and norethindroneacetate.
 18. The kit according to claim 17, wherein each group ofdosages of the Phase I composition contains about 5 dosages, each groupof dosages of the Phase II composition contains about 11 to about 14dosages, and each group of dosages of the Phase III composition containsabout 5 dosages.
 19. The kit according to claim 15, wherein the ethinylestradiol equivalent amount of estrogen in the Phase I composition isabout 25 mcg of ethinyl estradiol, the ethinyl estradiol equivalentamount of estrogen in the Phase II composition is about 30 mcg ofethinyl estradiol, and the ethinyl estradiol equivalent amount ofestrogen in the Phase III composition is about 25 mcg of ethinylestradiol.
 20. The kit according to claim 19, wherein the estrogen andprogestogen in the Phase I, II and III compositions are, respectively,ethinyl estradiol and norethindrone acetate.
 21. The kit according toclaim 20, wherein each group of dosages of the Phase I compositioncontains about 5 dosages, each group of dosages of the Phase IIcomposition contains about 11 to about 14 dosages, and each group ofdosages of the Phase III composition contains about 5 dosages.